Immunocore Holdings plc Sustainability Profile
Immunocore Holdings plc, a pioneering biotechnology company headquartered in Great Britain, is at the forefront of developing innovative T cell receptor (TCR) therapies for cancer and other serious diseases. Founded in 2008, Immunocore has made significant strides in the biopharmaceutical industry, particularly with its proprietary ImmTAC platform, which harnesses the power of T cells to target and destroy cancer cells. With a strong operational presence in Europe and North America, Immunocore has established itself as a leader in the field of immuno-oncology. The company’s flagship product, tebentafusp, has garnered attention for its unique mechanism of action and has received regulatory approvals for treating metastatic uveal melanoma. Recognised for its commitment to advancing cancer treatment, Immunocore continues to push the boundaries of science, positioning itself as a key player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Immunocore Holdings plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Immunocore Holdings plc's score of 25 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Immunocore Holdings plc's reported carbon emissions
In 2022, Immunocore Holdings plc reported a carbon footprint of approximately 0.0824 kg CO2e per unit of revenue, with total revenue of about USD 174,361,000. For 2023, the company did not disclose specific emissions data but reported a GHG intensity of investee companies at approximately 0.61722 kg CO2e per unit of revenue, with total revenue of about USD 249,428,000. Immunocore has not set specific reduction targets or disclosed any climate pledges. The company does not have available data for Scope 1, Scope 2, or Scope 3 emissions, indicating a lack of detailed emissions reporting. As of now, there are no cascaded emissions data from parent or related organizations, and all information is sourced directly from Immunocore Holdings plc. Overall, while Immunocore is beginning to report on its emissions intensity, it has yet to establish comprehensive climate commitments or reduction initiatives.
How Carbon Intensive is Immunocore Holdings plc's Industry?
How Carbon Intensive is Immunocore Holdings plc's Location?
Immunocore Holdings plc's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Immunocore Holdings plc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
